Roth Capital Trims PT on GenVec (GNVC) to $2 Following CGF166 Clinical Hold Lift
Tweet Send to a Friend
Roth Capital lowered its price target on Buy-rated GenVec, Inc. (Nasdaq: GNVC) from $8 down to $2 after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
